Insider · CIK 0001808365
Julius Knowles
Files at KROS (Keros Therapeutics, Inc.). First filing Jun 8, 2026, latest Jun 8, 2026.
In brief
Julius Knowles files SEC Form 4 as director at KROS (Keros Therapeutics, Inc.). Since Jun 8, 2026, Julius Knowles has reported 0 open-market buys worth $0 and 1 open-market sell worth $28k, the latest filed on Jun 8, 2026.
A track record needs three past buys with six months of prices behind them; Julius Knowles has 0, so none is measured yet.
The newest scored trade: sold $28k of KROS on Jun 4, 2026, filed Jun 8, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $28k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KROS: Keros Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Keros Therapeutics, Inc. | $28k 2,625 shares | -19% | +9% from low-51% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 4, 2026 | KROS Keros Therapeutics, Inc. | 2,625 0.01% of outstanding | $28k | Jun 4, 2026 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | KROS Keros Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,625 | $10.73 | $28k | 10,958 | Jun 8, 2026 |
| Jun 3, 2026 | KROS Keros Therapeutics, Inc. | AGrant or award Common Stock | +7,142 | $0.00 | $0 | 13,583 | Jun 5, 2026 |
| Jun 3, 2026 | KROS Keros Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,433 | $0.00 | $0 | 7,433 | Jun 5, 2026 |
| Nov 21, 2025 | KROS Keros Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: See footnote | -191,527 | $17.75 | $3.4M | 150,047 | Dec 18, 2025 |
| Nov 21, 2025 | KROS Keros Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: See footnote | -130,494 | $17.75 | $2.3M | 102,233 | Dec 18, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Common Stock | +5,250 | $0.00 | $0 | 6,441 | Jun 6, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,500 | $0.00 | $0 | 10,500 | Jun 6, 2025 |
Questions about Julius Knowles
Answered from the filings on this page, as of the latest one.
Is Julius Knowles buying or selling?
In the last 12 months Julius Knowles reported 0 open-market buys worth $0 and 1 open-market sell worth $28k on SEC Form 4; the latest was sold $28k of KROS on Jun 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Julius Knowles's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Julius Knowles has 0.
Where does Julius Knowles file Form 4?
Julius Knowles has filed Form 4 at KROS (Keros Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.